Nuformix reported a reduced interim loss and a significantly improved cash position for the six months ended 31 March 2026, supported by successful fundraisings and progress with NXP002, including FDA..
Executive Director Dr Dan Gooding discusses Nuformix’s NXP002 programme for idiopathic pulmonary fibrosis, the value of FDA orphan drug designation, and how the recent fundraise supports partnering discussions...
Nuformix strengthens its NXP002 programme with US orphan drug designation, unlocking market exclusivity in a region accounting for the majority of IPF revenues. With fresh capital and ongoing partner discussions,..
Nuformix plc has raised £1.0 million via a placing of 500 million new shares at 0.20p each. The proceeds will support additional pre-clinical studies and further development of its inhaled..
The FDA has granted Orphan Drug Designation to tranilast lystate, the active compound in Nuformix’s NXP002 programme targeting idiopathic pulmonary fibrosis, a rare lung disease affecting fewer than 200,000 people..
Nuformix has received an FDA request for clarification on its Orphan Drug Designation application for tranilast under the NXP002 programme. The company also reported its Open Offer was oversubscribed by..
Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic..
Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...
Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...
Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...
Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...
Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity..
Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...
Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...
Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...
Nuformix plc (LON:NFX) raises £168,750 for fibrosis drug development through a new share placing, advancing its NXP002 programme and corporate goals...
Nuformix reported a reduced interim loss and a significantly improved cash position for the six months ended 31 March 2026, supported by successful fundraisings and progress with NXP002, including FDA Orphan Drug Designation in IPF...
Executive Director Dr Dan Gooding discusses Nuformix’s NXP002 programme for idiopathic pulmonary fibrosis, the value of FDA orphan drug designation, and how the recent fundraise supports partnering discussions...
Nuformix strengthens its NXP002 programme with US orphan drug designation, unlocking market exclusivity in a region accounting for the majority of IPF revenues. With fresh capital and ongoing partner discussions, the company is positioning itself to advance a differentiated inhaled therapy while negotiating from strength...
Nuformix plc has raised £1.0 million via a placing of 500 million new shares at 0.20p each. The proceeds will support additional pre-clinical studies and further development of its inhaled NXP002 treatment for pulmonary fibrosis...
The FDA has granted Orphan Drug Designation to tranilast lystate, the active compound in Nuformix’s NXP002 programme targeting idiopathic pulmonary fibrosis, a rare lung disease affecting fewer than 200,000 people in the United States...
Nuformix has received an FDA request for clarification on its Orphan Drug Designation application for tranilast under the NXP002 programme. The company also reported its Open Offer was oversubscribed by 408%, raising around £228,000 before expenses...
Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis...
Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...
Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...
Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...
Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...
Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity and accelerated development support..
Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...
Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...
Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...
Nuformix plc (LON:NFX) raises £168,750 for fibrosis drug development through a new share placing, advancing its NXP002 programme and corporate goals...
